{"markup":"\u003C?xml version=\u00221.0\u0022 encoding=\u0022UTF-8\u0022 ?\u003E\n    \u003Chtml version=\u0022HTML+RDFa+MathML 1.1\u0022\n    xmlns:content=\u0022http:\/\/purl.org\/rss\/1.0\/modules\/content\/\u0022\n    xmlns:dc=\u0022http:\/\/purl.org\/dc\/terms\/\u0022\n    xmlns:foaf=\u0022http:\/\/xmlns.com\/foaf\/0.1\/\u0022\n    xmlns:og=\u0022http:\/\/ogp.me\/ns#\u0022\n    xmlns:rdfs=\u0022http:\/\/www.w3.org\/2000\/01\/rdf-schema#\u0022\n    xmlns:sioc=\u0022http:\/\/rdfs.org\/sioc\/ns#\u0022\n    xmlns:sioct=\u0022http:\/\/rdfs.org\/sioc\/types#\u0022\n    xmlns:skos=\u0022http:\/\/www.w3.org\/2004\/02\/skos\/core#\u0022\n    xmlns:xsd=\u0022http:\/\/www.w3.org\/2001\/XMLSchema#\u0022\n    xmlns:mml=\u0022http:\/\/www.w3.org\/1998\/Math\/MathML\u0022\u003E\n  \u003Chead\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_itu2PgFdrjV-docKmLK8Jn5oXe_05RgvQh73eOhI_mE.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_at_symbol.js?nzllu1\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_article_reference_popup.js?nzllu1\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_I8yX6RYPZb7AtMcDUA3QKDZqVkvEn35ED11_1i7vVpc.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\n(function(i,s,o,g,r,a,m){i[\u0022GoogleAnalyticsObject\u0022]=r;i[r]=i[r]||function(){(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)})(window,document,\u0022script\u0022,\u0022\/\/www.google-analytics.com\/analytics.js\u0022,\u0022ga\u0022);ga(\u0022create\u0022, \u0022UA-15605596-27\u0022, {\u0022cookieDomain\u0022:\u0022auto\u0022});ga(\u0022set\u0022, \u0022page\u0022, location.pathname + location.search + location.hash);ga(\u0022send\u0022, \u0022pageview\u0022);ga(\u0027create\u0027, \u0027UA-189672-26\u0027, \u0027auto\u0027, {\u0027name\u0027: \u0027hwTracker\u0027});\r\nga(\u0027hwTracker.send\u0027, \u0027pageview\u0027);\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\njQuery.extend(Drupal.settings, {\u0022basePath\u0022:\u0022\\\/\u0022,\u0022pathPrefix\u0022:\u0022\u0022,\u0022highwire\u0022:{\u0022markup\u0022:[{\u0022requested\u0022:\u0022full-text\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;15\\\/48\\\/8\u0022},{\u0022requested\u0022:\u0022long\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;15\\\/48\\\/8\u0022}],\u0022ac\u0022:{\u0022spmdc;15\\\/48\\\/8\u0022:{\u0022access\u0022:{\u0022reprint\u0022:true,\u0022full\u0022:true},\u0022pisa_id\u0022:\u0022spmdc;15\\\/48\\\/8\u0022,\u0022atom_uri\u0022:\u0022\u0022,\u0022jcode\u0022:\u0022spmdc\u0022}}},\u0022googleanalytics\u0022:{\u0022trackOutbound\u0022:1,\u0022trackMailto\u0022:1,\u0022trackDownload\u0022:1,\u0022trackDownloadExtensions\u0022:\u00227z|aac|arc|arj|asf|asx|avi|bin|csv|doc(x|m)?|dot(x|m)?|exe|flv|gif|gz|gzip|hqx|jar|jpe?g|js|mp(2|3|4|e?g)|mov(ie)?|msi|msp|pdf|phps|png|ppt(x|m)?|pot(x|m)?|pps(x|m)?|ppam|sld(x|m)?|thmx|qtm?|ra(m|r)?|sea|sit|tar|tgz|torrent|txt|wav|wma|wmv|wpd|xls(x|m|b)?|xlt(x|m)|xlam|xml|z|zip\u0022,\u0022trackUrlFragments\u0022:1},\u0022ajaxPageState\u0022:{\u0022js\u0022:{\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/jquery.cluetip.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.hoverIntent.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.bgiframe.min.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_at_symbol.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_article_reference_popup.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/contrib\\\/google_analytics\\\/googleanalytics.js\u0022:1,\u00220\u0022:1}}});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/cdn\/css\/http\/css_Xg7z6oCTVgud_Q0huYz9x9iiD5H_2YPSJ5z2ZViSWdY.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink rel=\u0027stylesheet\u0027 type=\u0027text\/css\u0027 href=\u0027\/sites\/all\/modules\/contrib\/panels\/plugins\/layouts\/onecol\/onecol.css\u0027 \/\u003E\u003C\/head\u003E\u003Cbody\u003E\u003Cdiv class=\u0022panels-ajax-tab-panel panels-ajax-tab-panel-sageoa-tab-art\u0022\u003E\u003Cdiv class=\u0022panel-display panel-1col clearfix\u0022 \u003E\n  \u003Cdiv class=\u0022panel-panel panel-col\u0022\u003E\n    \u003Cdiv\u003E\u003Cdiv class=\u0022panel-pane pane-highwire-markup\u0022 \u003E\n  \n      \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv class=\u0022highwire-markup\u0022\u003E\u003Cdiv xmlns=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022 id=\u0022content-block-markup\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cdiv class=\u0022article fulltext-view \u0022\u003E\u003Cspan class=\u0022highwire-journal-article-marker-start\u0022\u003E\u003C\/span\u003E\u003Cdiv class=\u0022section abstract\u0022 id=\u0022abstract-1\u0022\u003E\u003Ch2\u003ESummary\u003C\/h2\u003E\u003Cp id=\u0022p-1\u0022\u003EData from the SECURE trial suggested that isavuconazole was not inferior to voriconazole when treating invasive fungal diseases. Data from 2 subsets of SECURE now show that patients taking isavuconazole are less likely to suffer from treatment-emergent adverse events and that the drug is both safe and effective for obese patients.\u003C\/p\u003E\u003C\/div\u003E\u003Cul class=\u0022kwd-group\u0022\u003E\u003Cli class=\u0022kwd\u0022\u003Eisavuconazole\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Evoriconazole\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003ESECURE trial\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Einvasive fungal diseases\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Esafety\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Eobesity\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Einfectious diseases clinical trials\u003C\/li\u003E\u003C\/ul\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-1\u0022\u003E\u003Cp id=\u0022p-2\u0022\u003EIsavuconazole (ISA) is a novel, water-soluble, broad-spectrum triazole antifungal agent developed for the treatment of invasive fungal diseases (IFDs), including invasive aspergillosis. These are rare infections that occur typically in immunocompromised, critically ill patients. By disrupting fungal membrane structure and function, ISA is active against all major opportunistic and pathologic fungi [Seyedmousavi S et al. \u003Cem\u003EExpert Rev Anti Infec Ther\u003C\/em\u003E. 2015]. ISA was approved by the FDA for the treatment of aspergillosis and mucormycosis in March 2015.\u003C\/p\u003E\u003Cp id=\u0022p-3\u0022\u003EThe SECURE trial [\u003Ca class=\u0022external-ref external-ref-type-clintrialgov\u0022 href=\u0022\/lookup\/external-ref?link_type=CLINTRIALGOV\u0026amp;access_num=NCT00412893\u0026amp;atom=%2Fspmdc%2F15%2F48%2F8.atom\u0022\u003ENCT00412893\u003C\/a\u003E] investigated the safety and efficacy of ISA as compared with voriconazole (VRC) in patients with IFD caused by \u003Cem\u003EAspergillus\u003C\/em\u003E spp and other filamentous fungi. SECURE was a large (n\u2005=\u2005516) phase 3 double-blind randomized trial that demonstrated the noninferiority of ISA compared with VRC for all-cause mortality at day 42 in the intention-to-treat population (ISA, 18.6%; VRC, 20.2%; 95% CI, \u22127.8 to 5.7) [Maertens J et al. ECCMID 2014 (abstr O230a)].\u003C\/p\u003E\u003Cp id=\u0022p-4\u0022\u003ETwo presenters in this session reported additional, more detailed safety and outcomes data from SECURE. Andrew J. Ullmann, MD, University of W\u00fcrzburg, W\u00fcrzburg, Germany, presented information regarding the development of treatment-emergent adverse events (TEAEs) in both the ISA and VRC groups. A TEAE was defined as any adverse event after the first administration of the drug until 28 days following the last administration.\u003C\/p\u003E\u003Cp id=\u0022p-5\u0022\u003EAmong patients in the ISA group, 96% experienced at least 1 TEAE, compared with 98% in the VRC group. This was an expected finding related to the severity of the patients\u2019 underlying illnesses. However, when analyzed by system organ class, moderate or severe TEAEs in the ISA group were lower in 19 of the 24 classes. In the comparison of the ISA and VRC groups, a significant difference was seen in disorders of the eye (15% vs 27%; \u003Cem\u003EP\u003C\/em\u003E\u2005\u0026lt;\u2005.01), skin (33% vs 42%; \u003Cem\u003EP\u003C\/em\u003E\u2005\u0026lt;\u2005.05), and hepatobiliary system (9% vs 16%; \u003Cem\u003EP\u003C\/em\u003E\u2005\u0026lt;\u2005.05). Overall, the rate of treatment-related TEAEs was significantly lower in the ISA group than the VRC group (42% vs 60%, \u003Cem\u003EP\u003C\/em\u003E\u2005\u0026lt;\u2005.01). Psychiatric (27% vs 33%) and cardiac (17% vs 22%) events were also lower in the ISA group vs the VRC group; however, this difference was not statistically significant.\u003C\/p\u003E\u003Cp id=\u0022p-6\u0022\u003EProf Ullmann suggested that the difference in TEAEs favoring ISA was influenced primarily by 4 factors: disorders of the eye, the hepatobiliary system, investigations (including elevations in hepatic enzymes), and psychiatric disorders.\u003C\/p\u003E\u003Cp id=\u0022p-7\u0022\u003EDebra Goff, PharmD, Ohio State University, Columbus, Ohio, USA, presented safety and outcomes in obese patients (body mass index [BMI] \u2265\u200530 kg\/m\u003Csup\u003E2\u003C\/sup\u003E) enrolled in the SECURE trial. The analysis was done on patients with proven\/probable IFD treated with either ISA or VRC who were categorized into 3 BMI classifications: \u0026lt;\u200525, 25 to \u0026lt;\u200530, and \u2265\u200530 kg\/m\u003Csup\u003E2\u003C\/sup\u003E.\u003C\/p\u003E\u003Cp id=\u0022p-8\u0022\u003EOf the 527 randomized patients, 263 had proven\/probable IFD and BMI data available; 25 patients were obese (ISA, n\u2005=\u200515; VRC, n\u2005=\u200510). All-cause mortality through day 42 was comparable between treatment arms in obese patients (1 vs 2 patients; adjusted difference, \u201313.3; 95% CI, \u221250.9 to 24.2). Similar numbers of obese patients responded successfully to either ISA or VRC (6 vs 4; adjusted difference, 0.0; 95% CI, \u221249.4 to 49.4). Drug-related TEAEs (40% vs 70%), serious TEAEs (53% vs 90%), and deaths (27% vs 40%) were less frequent in obese patients treated with ISA compared with VRC.\u003C\/p\u003E\u003Cp id=\u0022p-9\u0022\u003EDr Goff concluded that in this small subgroup of obese patients, ISA outcomes were comparable with VRC and similar to those of the other BMI subgroups. Among a small group of obese patients, there were fewer drug-related TEAEs, serious TEAEs, and deaths reported in those treated with ISA vs VRC.\u003C\/p\u003E\u003C\/div\u003E\u003Cul class=\u0022copyright-statement\u0022\u003E\u003Cli class=\u0022fn\u0022 id=\u0022copyright-statement-1\u0022\u003E\u00a9 2015 SAGE Publications\u003C\/li\u003E\u003C\/ul\u003E\u003Cspan class=\u0022highwire-journal-article-marker-end\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Cspan id=\u0022related-urls\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Ca href=\u0022http:\/\/mdc.sagepub.com\/content\/15\/48\/8.abstract\u0022 class=\u0022hw-link hw-link-article-abstract\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView Summary\u003C\/a\u003E\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E\n\u003C\/div\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_openurl.js?nzllu1\u0022\u003E\u003C\/script\u003E\n\u003C\/body\u003E\u003C\/html\u003E"}